These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 37770957

  • 1. Cystine/glutamate antiporter xCT deficiency reduces metastasis without impairing immune system function in breast cancer mouse models.
    Ruiu R, Cossu C, Iacoviello A, Conti L, Bolli E, Ponzone L, Magri J, Rumandla A, Calautti E, Cavallo F.
    J Exp Clin Cancer Res; 2023 Sep 29; 42(1):254. PubMed ID: 37770957
    [Abstract] [Full Text] [Related]

  • 2. Immunotargeting of the xCT Cystine/Glutamate Antiporter Potentiates the Efficacy of HER2-Targeted Immunotherapies in Breast Cancer.
    Conti L, Bolli E, Di Lorenzo A, Franceschi V, Macchi F, Riccardo F, Ruiu R, Russo L, Quaglino E, Donofrio G, Cavallo F.
    Cancer Immunol Res; 2020 Aug 29; 8(8):1039-1053. PubMed ID: 32532810
    [Abstract] [Full Text] [Related]

  • 3. Cystine-glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity.
    Arensman MD, Yang XS, Leahy DM, Toral-Barza L, Mileski M, Rosfjord EC, Wang F, Deng S, Myers JS, Abraham RT, Eng CH.
    Proc Natl Acad Sci U S A; 2019 May 07; 116(19):9533-9542. PubMed ID: 31019077
    [Abstract] [Full Text] [Related]

  • 4. The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility.
    Shin CS, Mishra P, Watrous JD, Carelli V, D'Aurelio M, Jain M, Chan DC.
    Nat Commun; 2017 Apr 21; 8():15074. PubMed ID: 28429737
    [Abstract] [Full Text] [Related]

  • 5. Immunotargeting of Antigen xCT Attenuates Stem-like Cell Behavior and Metastatic Progression in Breast Cancer.
    Lanzardo S, Conti L, Rooke R, Ruiu R, Accart N, Bolli E, Arigoni M, Macagno M, Barrera G, Pizzimenti S, Aurisicchio L, Calogero RA, Cavallo F.
    Cancer Res; 2016 Jan 01; 76(1):62-72. PubMed ID: 26567138
    [Abstract] [Full Text] [Related]

  • 6. xCT knockdown in human breast cancer cells delays onset of cancer-induced bone pain.
    Ungard RG, Linher-Melville K, Nashed MG, Sharma M, Wen J, Singh G.
    Mol Pain; 2019 Jan 01; 15():1744806918822185. PubMed ID: 30799686
    [Abstract] [Full Text] [Related]

  • 7. Identification, Expression, and Roles of the Cystine/Glutamate Antiporter in Ocular Tissues.
    Martis RM, Knight LJ, Donaldson PJ, Lim JC.
    Oxid Med Cell Longev; 2020 Jan 01; 2020():4594606. PubMed ID: 32655769
    [Abstract] [Full Text] [Related]

  • 8. Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance.
    Lim JKM, Delaidelli A, Minaker SW, Zhang HF, Colovic M, Yang H, Negri GL, von Karstedt S, Lockwood WW, Schaffer P, Leprivier G, Sorensen PH.
    Proc Natl Acad Sci U S A; 2019 May 07; 116(19):9433-9442. PubMed ID: 31000598
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Genetic Ablation of the Cystine Transporter xCT in PDAC Cells Inhibits mTORC1, Growth, Survival, and Tumor Formation via Nutrient and Oxidative Stresses.
    Daher B, Parks SK, Durivault J, Cormerais Y, Baidarjad H, Tambutte E, Pouysségur J, Vučetić M.
    Cancer Res; 2019 Aug 01; 79(15):3877-3890. PubMed ID: 31175120
    [Abstract] [Full Text] [Related]

  • 17. Loss of the cystine/glutamate antiporter in melanoma abrogates tumor metastasis and markedly increases survival rates of mice.
    Sato M, Onuma K, Domon M, Hasegawa S, Suzuki A, Kusumi R, Hino R, Kakihara N, Kanda Y, Osaki M, Hamada J, Bannai S, Feederle R, Buday K, Angeli JPF, Proneth B, Conrad M, Okada F, Sato H.
    Int J Cancer; 2020 Dec 01; 147(11):3224-3235. PubMed ID: 32818320
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cystine-glutamate antiporter deletion accelerates motor recovery and improves histological outcomes following spinal cord injury in mice.
    Sprimont L, Janssen P, De Swert K, Van Bulck M, Rooman I, Gilloteaux J, Massie A, Nicaise C.
    Sci Rep; 2021 Jun 09; 11(1):12227. PubMed ID: 34108554
    [Abstract] [Full Text] [Related]

  • 20. Fighting breast cancer stem cells through the immune-targeting of the xCT cystine-glutamate antiporter.
    Ruiu R, Rolih V, Bolli E, Barutello G, Riccardo F, Quaglino E, Merighi IF, Pericle F, Donofrio G, Cavallo F, Conti L.
    Cancer Immunol Immunother; 2019 Jan 09; 68(1):131-141. PubMed ID: 29947961
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.